Based on our findings suggesting that DARPP-32 increases ERBB3 phosphorylation to bypass gefitinib-induced EGFR inhibition, we next sought to understand whether DARPP-32 drives NSCLC resistance to EGFR TKIs in vivo. This evidence concerns the gene EGFR and non-small cell lung carcinoma.